Massachusetts General Hospital (MGH) & Harvard Medical School, US

Dr. J. Keith Joung is Associate Chief of Pathology for Research at Massachusetts General Hospital (MGH) and Associate Professor of Pathology at Harvard Medical School. He received his M.D. and Ph.D. degrees from Harvard Medical School and did post-doctoral research with Carl Pabo at the Massachusetts Institute of Technology. Dr. Joung’s research interests are in the development and application of engineered DNA-binding domains and customized nucleases. Over the past five years, his lab has pioneered methods for targeted genome editing using engineered zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas RNA guided nucleases (RGNs). Dr. Joung is the recipient of a NIH Director’s Pioneer Award, a NIH Transformative R01 award, and the Jim and Ann Orr MGH Research Scholar award.

^ Synergistic regulation of human gene expression using TALE activators.
Maeder ML, Linder SJ, Reyon D, Angstman JF, Fu Y, Sander JD, Joung JK. Robust,
Nat Methods. 2013 Mar;10(3):243-5.
^ Efficient genome editing in zebrafish using a CRISPR-Cas system.
Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK.
Nat Biotechnol. 2013 Mar;31(3):227-9.
^ FLASH assembly of TALENs for high-throughput genome editing.
Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK.
Nat Biotechnol. 2012 May;30(5):460-5.
^ TALENs: a widely applicable technology for targeted genome editing.
Joung JK, Sander JD.
Nat Rev Mol Cell Biol. 2013 Jan;14(1):49-55. Review.
^ Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA).
Sander JD, Dahlborg EJ, Goodwin MJ, Cade L, Zhang F, Cifuentes D, Curtin SJ, Blackburn JS, Thibodeau-Beganny S, Qi Y, Pierick CJ, Hoffman E, Maeder ML, Khayter C, Reyon D, Dobbs D, Langenau DM, Stupar RM, Giraldez AJ, Voytas DF, Peterson RT, Yeh JR, Joung JK.
Nat Methods. 2011 Jan;8(1):67-9.